IRS1

Amazon Business Adds Affirm as First Buy Now, Pay Later Provider at Checkout

Retrieved on: 
Thursday, November 2, 2023
Banking, Mobile, Wireless, Professional Services, Online Retail, Internet, Business, Payments, Electronic Commerce, Apps, Applications, Technology, Small Business, Retail, Finance, Black Friday, Growth, Amazon (company), APR, Small business, Partnership, AMZN, IRS1, Multimedia, Online shopping, Amazon

Now, these Amazon Business customers can split the total cost of eligible purchases and pay over time with Affirm without late or hidden fees.

Key Points: 
  • Now, these Amazon Business customers can split the total cost of eligible purchases and pay over time with Affirm without late or hidden fees.
  • Amazon Business will start to roll out Affirm today to eligible sole proprietor businesses, and the new payment option will be available at checkout to all eligible Amazon Business sole proprietor customers by Black Friday.
  • By selecting Affirm at checkout on Amazon Business and entering a few simple pieces of information, such as registered business name and business address, small business owners will receive an instant credit decision.
  • Customers looking to use Affirm through Amazon Business can do so using the Amazon Business website and Amazon Business mobile app.

Purple Biotech Reports First Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, May 16, 2023
PDAC, NETS, Table, Neoplasm, Survival, ICB, Protein, Acquisition, CEACAM1, Patient, 5T4, SAB, Coronavirus Scientific Advisory Board, NK, Research, NET, Net, CD8, Average cost, TME, Neutrophil extracellular traps, PD-1, Safety, Cancer, STAT3, AACR, International, Papillary thyroid cancer, Therapeutic index, American Association for Cancer Research, Biomarker, SOC, MD Anderson Cancer Center, Jefferies Group, Administration, CM24, University, TASE, Immune system, Escape Room, Infrared spectroscopy correlation table, CRC, IRS1, ADS, Cetuximab, Trial of the century, Drug resistance, State Administrative Expenses, Clinical trial, Tumor microenvironment, Nivolumab, Pharmaceutical industry, Vaccine

REHOVOT, Israel, May 16, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced financial results for the three months ended March 31, 2023.

Key Points: 
  • The acquisition provides Purple Biotech with a technology platform for tri-specific antibody compounds and offers the potential to further expand to additional targets.
  • On March 16, 2023, Purple Biotech shared new results from exploratory analyses from a Phase 1 dose escalation study that assessed the safety and tolerability of CM24 plus nivolumab ( NCT04731467 ).
  • On April 19, 2023, Purple Biotech announced research findings at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando.
  • Purple Biotech announced on April 25, 2023, the inauguration of its Scientific Advisory Board (SAB).

Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitors

Retrieved on: 
Wednesday, April 19, 2023
STAT3, AACR, Phosphorylation, Myeloid-derived suppressor cell, IRS1, Neoplasm, American Association for Cancer Research, Hope, NK, ICB, Doctor of Philosophy, MD Anderson Cancer Center, Drug resistance, Protein, CD8, Patient, Melanoma, University, Annual general meeting, TME, Escape Room, Mouse, Tumor microenvironment, Pharmaceutical industry, Medical imaging

REHOVOT, Israel, April 19, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies that harness the power of the tumor microenvironment (TME) to overcome tumor immune evasion and drug resistance, today shared new results presented at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando. The results demonstrate the potential of NT219, the Company’s novel small molecule dual inhibitor of IRS1/2 and STAT3 escape mechanisms, to work synergistically with either anti-PD1 or anti-CTLA4 drugs to reprogram the immune profile in the TME and convert resistant tumors to responders to Immune Checkpoint Blockage (ICB) therapies. The study was led by researchers at The University of Texas MD Anderson Cancer Center. Main results are as follows:

Key Points: 
  • The study was led by researchers at The University of Texas MD Anderson Cancer Center.
  • The induction of PDL1 by NT219 was much higher in the ICB-resistant melanoma strain as compared to ICB-sensitive cells, suggesting the potential to re-sensitize refractory tumors to anti-PD1 therapy.
  • Similarly, NT219 in combination with anti-PD1 showed synergistic effects inducing significant tumor growth inhibition of ICB-resistant tumors, while each therapy alone had no effect.
  • The full poster can be viewed on the Purple Biotech Website at https://purple-biotech.com/pipeline/#1Publications.

Purple Biotech Announces Publication in Nature Cancer Demonstrating Mechanisms Behind Cancer Cell Persistence Frequency and Potential of NT219 to Reduce Therapeutic Resistance

Retrieved on: 
Friday, October 22, 2021
CM24, Head, Phenotype, Pancreatic cancer, EGFR, Recurrence, Phosphorylation, Cancer, Cetuximab, Drug development, Survival, SCCHN, Patient, Private Securities Litigation Reform Act, Large-cell lung carcinoma, Apoptosis, Food, Serine, U.S. Securities and Exchange Commission, SEC, Weizmann Institute of Science, Doctor of Philosophy, PD-1, Regulation of tobacco by the U.S. Food and Drug Administration, Annual report, Forward-looking statement, Marketing, CEACAM1, Patent, Company, Risk, Bristol Myers Squibb, Intention, IRS1, List of Nature Research journals, NASDAQ, Nivolumab, Development, IRS, Drug resistance, GLOBE, CTP, Department, Legislation, Neck, STAT3, Pharmaceutical industry

REHOVOT, Israel, Oct. 22, 2021 (GLOBE NEWSWIRE) --  Purple Biotech (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today announced a publication in Nature Cancer that provides new insight into the underlying mechanism of the therapeutic resistance of cancer cells and the significant role of insulin receptor substrate 1 (IRS1) pathway on epithelial growth factor receptor (EFGR) inhibition therapy. NT219, currently being evaluated in a Phase 1/2 clinical trial, is a novel small molecule inhibiting simultaneously IRS1/2 and STAT3.

Key Points: 
  • NT219, currently being evaluated in a Phase 1/2 clinical trial, is a novel small molecule inhibiting simultaneously IRS1/2 and STAT3.
  • The lead author of the publication is Ravid Straussman, M.D., Ph.D., Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
  • The article demonstrated mechanistic evidence of cancer cells' inherited therapeutic resistance, termed chance to persist (CTP).
  • Purple Biotech Ltd. is a clinical-stage company developing first-in-class therapies by overcoming tumor immune evasion and drug resistance.

BridgeBio Announces Clinical Collaboration with Bristol Myers Squibb to Study BBP-398, a Potentially Best-in-class SHP2 Inhibitor, in Combination with OPDIVO® (nivolumab) in Advanced Solid Tumors with KRAS Mutations

Retrieved on: 
Tuesday, July 27, 2021
Enzymes, Branches of biology, Signal transduction, Mitogen-activated protein kinase, Ras GTPase, PTPN11, Programmed cell death protein 1, Nivolumab, IRS1, MAPK/ERK pathway

Under the terms of the non-exclusive collaboration, BridgeBio will sponsor the study and Bristol Myers Squibb will provide nivolumab.

Key Points: 
  • Under the terms of the non-exclusive collaboration, BridgeBio will sponsor the study and Bristol Myers Squibb will provide nivolumab.
  • Both BridgeBio and Bristol Myers Squibb will share the cost of clinical development activities for the combination trial.
  • SHP2 is a protein-tyrosine phosphatase that links growth factor, cytokine and integrin signaling with the downstream RAS/ERK MAPK pathway to regulate cellular proliferation and survival.
  • Combination of anti-PD-1 treatment with BBP-398, and other targeted therapies, could be promising for patients with KRAS mutations.

Kitov Pharma Receives Notice of Allowance for a U.S. Patent Covering its Anti-Cancer Drug Candidate, NT219

Retrieved on: 
Tuesday, October 27, 2020
Branches of biology, Clinical medicine, Medicine, Oncology, Signal transduction, Antineoplastic drugs, Cancer treatments, IRS1, Drug resistance, STAT3, Chemotherapy

The patent, which expires in 2036, covers Kitovs NT219, a dual inhibitor, novel small molecule targeting IRS1/2 and STAT3, important oncogenic drivers and major drug resistance pathways in many hard-to-treat cancers.

Key Points: 
  • The patent, which expires in 2036, covers Kitovs NT219, a dual inhibitor, novel small molecule targeting IRS1/2 and STAT3, important oncogenic drivers and major drug resistance pathways in many hard-to-treat cancers.
  • These encouraging results suggest a potentially promising therapeutic avenue for NT219 that Kitov intends to explore in future clinical trials.
  • Kitov Pharma Ltd. (Kitov; NASDAQ/TASE: KTOV) is a clinical-stage company focusing on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, to create successful long-lasting treatments for people with cancer.
  • NT219 is a small molecule targeting the novel cancer drug resistance pathways IRS1/2 and STAT3.